Abstract
Parkinson’s disease is characterized by progressive neuronal degeneration of dopaminergic neurons in the substantia nigra. Many factors are thought to contribute to the neuronal cell death that occurs in Parkinson’s disease, including α-synuclein-mediated toxicity. Previously, we have reported that α-synuclein directly couples to the carboxyl tail of the dopamine transporter (DAT) and that the α-synuclein/DAT protein complex formation accelerates DAT-mediated cellular dopamine (DA) uptake and DA-induced cellular apoptosis. In the present study, we report that parkin, an E2-dependent E3 protein ubiquitin ligase associated with recessive early onset Parkinson’s disease, exerts a protective effect against DA-induced α-synuclein-dependent cell toxicity. Parkin impairs the α-synuclein/DAT coupling by interacting with the carboxyl-terminus of the DAT and blocks the α-synuclein-induced enhancement in both DAT cell surface expression and DAT-mediated DA uptake. Moreover, we have found that parkin protects against DA-induced cell toxicity in dopaminergic SK-N-SH cells. These findings will help identify the role of these proteins in the etiology and/or maintenance of Parkinson’s disease.
Similar content being viewed by others
Abbreviations
- DA:
-
dopamine
- DAT:
-
dopamine transporter
- GST:
-
glutathione S-transferase
- HEK:
-
human embryonic kidney
- PBS:
-
phosphate-buffered saline
- PD:
-
Parkinson’s disease
- PI:
-
propidium iodide
- ROS:
-
reactive oxygen species
References
Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., et al. (2000). Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239–252.
Aguilar, R. C., & Wendland, B. (2003). Ubiquitin: Not just for proteasomes anymore. Current Opinion in Cell Biology, 15, 184–190.
Asanuma, M., Miyazaki, I., & Ogawa, N. (2003). Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotoxicity Research, 5, 165–176.
Bianchi, P., Seguelas, M. H., Parini, A., & Cambon, C. (2003). Activation of pro-apoptotic cascade by dopamine in renal epithelial cells is fully dependent on hydrogen peroxide generation by monoamine oxidases. Journal of the American Society of Nephrology, 14, 855–862.
Chen, N., & Reith, M. E. (2000). Structure and function of the dopamine transporter. European Journal of Pharmacology, 405, 329–339.
Choi, P., Golts, N., Snyder, H., Chong, M., Petrucelli, L., Hardy, J., et al. (2001). Co-association of parkin and alpha-synuclein. Neuroreport, 12, 2839–2843.
Chung, K. K., Dawson, V. L., & Dawson, T. M. (2003). New insights into Parkinson’s disease. Journal of Neurology, 250(Suppl 3), III15–24.
Chung, K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., et al. (2001). Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Natural Medicines, 7, 1144–1150.
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., et al. (2006). Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature, 441, 1162–1166.
Daniels, G. M., & Amara, S. G. (1999). Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. Journal of Biological Chemistry, 274, 35794–35801.
Forno, L. S. (1996). Neuropathology of Parkinson’s disease. Journal of Neuropathology and Experimental Neurology, 55, 259–272.
Gerlach, M., Riederer, P., & Youdim, M. B. (1996). Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Advances in Neurology, 69, 177–194.
Giasson, B. I., & Lee, V. M. (2001). Parkin and the molecular pathways of Parkinson’s disease. Neuron, 31, 885–888.
Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., et al. (2003). Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. Journal of Biological Chemistry, 278, 43628–43635.
Graham, D. G. (1978). Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Molecular Pharmacology, 14, 633–643.
Hershko, A., & Ciechanover, A. (1998). The ubiquitin system. Annual Reviews of Biochemical, 67, 425–479.
Hicke, L. (2001). Protein regulation by monoubiquitin. Nature Reviews. Molecular Cell Biology, 2, 195–201.
Hicke, L., & Dunn, R. (2003). Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annual Review of Cell and Developmental Biology, 19, 141–172.
Horn, A. S. (1990). Dopamine uptake: A review of progress in the last decade. Progress in Neurobiology, 34, 387–400.
Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., et al. (2000). Alpha-synuclein promotes mitochondrial deficit and oxidative stress. American Journal of Pathology, 157, 401–410.
Javitch, J. A., D’Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985). Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proceedings of the National Academy of Sciences of the United States of America, 82, 2173–2177.
Jenner, P., & Olanow, C. W. (1996). Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology, 47, S161–S170.
Jiang, H., Jiang, Q., & Feng, J. (2004a). Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. Journal of Biological Chemistry, 279, 54380–54386.
Jiang, H., Ren, Y., Zhao, J., & Feng, J. (2004b). Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Human Molecular Genetics, 13, 1745–1754.
Junn, E., & Mouradian, M. M. (2002). Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neuroscience Letters, 320, 146–150.
Katzmann, D. J., Odorizzi, G., & Emr, S. D. (2002). Receptor downregulation and multivesicular-body sorting. Nature Reviews. Molecular Cell Biology, 3, 893–905.
Kim, S. J., Sung, J. Y., Um, J. W., Hattori, N., Mizuno, Y., Tanaka, K., et al. (2003). Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. Journal of Biological Chemistry, 278, 41890–41899.
Kitayama, S., Shimada, S., & Uhl, G. R. (1992). Parkinsonism-inducing neurotoxin MPP+: Uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Annals of Neurology, 32, 109–111.
Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kösel, S., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nature Genetics, 18, 106–108.
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005). Dopamine covalently modifies and functionally inactivates parkin. Natural Medicines, 11, 1214–1221.
Lee, F. J., Liu, F., Pristupa, Z. B., & Niznik, H. B. (2001). Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB Journal, 15, 916–926.
Lee, F. J., Pristupa, Z. B., Ciliax, B. J., Levey, A. I., & Niznik, H. B. (1996). The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain. Journal of Biological Chemistry, 271, 20885–20894.
Lehmensiek, V., Tan, E. M., Schwarz, J., & Storch, A. (2002). Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. Neuroreport, 13, 1279–1283.
Lehmensiek, V., Tan, E. M., Liebau, S., Lenk, T., Zettlmeisl, H., Schwarz, J., et al. (2006). Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson’s disease. Neurochemistry International, 48, 329–340.
Lim, K. L., Chew, K. C., Tan, J. M., Wang, C., Chung, K. K., Zhang, Y., et al. (2005). Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: Implications for Lewy body formation. Journal of Neuroscience, 25, 2002–2009.
Liu, F., Wan, Q., Pristupa, Z. B., Yu, X. M., Wang, Y. T., & Niznik, H. B. (2000). Direct protein–protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature, 403, 274–280.
Lo Bianco, C., Ridet, J. L., Schneider, B. L., Deglon, N., & Aebischer, P. (2002). Alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proceedings of the National Academy of Sciences of the United States of America, 99, 10813–10818.
Lo Bianco, C., Schneider, B. L., Bauer, M., Sajadi, A., Brice, A., Iwatsubo, T., et al. (2004). Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson’s disease. Proceedings of the National Academy of Sciences of the United States of America, 101, 17510–17515.
Magasanik, B., & Kaiser, C. A. (2002). Nitrogen regulation in Saccharomyces cerevisiae. Gene, 290, 1–18.
Melikian, H. E., & Buckley, K. M. (1999). Membrane trafficking regulates the activity of the human dopamine transporter. Journal of Neuroscience, 19, 7699–7710.
Mortensen, O. V., & Amara, S. G. (2003). Dynamic regulation of the dopamine transporter. European Journal of Pharmacology, 479, 159–170.
Moussa, C. E., Wersinger, C., Tomita, Y., & Sidhu, A. (2004). Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Biochemistry, 43, 5539–5550.
Napolitano, A., Cesura, A. M., & Da Prada, M. (1995). The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. Journal of Neural Transmission. Supplementum, 45, 35–45.
Olanow, C. W., & Arendash, G. W. (1994). Metals and free radicals in neurodegeneration. Current Opinion in Neurology, 7, 548–558.
Oluwatosin-Chigbu, Y., Robbins, A., Scott, C. W., Arriza, J. L., Reid, J. D., & Zysk, J. R. (2003). Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells. Biochemical and Biophysical Research Communications, 309, 679–684.
Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., et al. (2004). Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. Journal of Biological Chemistry, 279, 18614–18622.
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., et al. (2006). Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature, 441, 1157–1161.
Pei, L., Lee, F. J., Moszczynska, A., Vukusic, B., & Liu, F. (2004). Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. Journal of Neuroscience, 24, 1149–1158.
Perez, R. G., & Hastings, T. G. (2004). Could a loss of alpha-synuclein function put dopaminergic neurons at risk? Journal of Neurochemistry, 89, 1318–1324.
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002). A role for alpha-synuclein in the regulation of dopamine biosynthesis. Journal of Neuroscience, 22, 3090–3099.
Petrucelli, L., O’Farrell, C., Lockhart, P. J., Baptista, M., Kehoe, K., Vink, L., et al. (2002). Parkin protects against the toxicity associated with mutant alpha-synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron, 36, 1007–1019.
Pickart, C. M. (2000). Ubiquitin in chains. Trends in Biochemical Sciences, 25, 544–548.
Pifl, C., Giros, B., & Caron, M. G. (1993). Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. Journal of Neuroscience, 13, 4246–4253.
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276, 2045–2047.
Pristupa, Z. B., McConkey, F., Liu, F., Man, H. Y., Lee, F. J., Wang, Y. T., et al. (1998). Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse, 30, 79–87.
Rawal, N., Periquet, M., Lohmann, E., Lücking, C. B., Teive, H. A., Ambrosio, G., et al. (2003). New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism. Neurology, 60, 1378–1381.
Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., et al. (2001). Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson’s disease. Science, 293, 263–269.
Shyu, W. C., Lin, S. Z., Chiang, M. F., Pang, C. Y., Chen, S. Y., Hsin, Y. L., et al. (2005). Early-onset Parkinson’s disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study. Parkinsonism & Related Disorders, 11, 173–180.
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). alpha-Synuclein locus triplication causes Parkinson’s disease. Science, 302, 841.
Torres, G. E. (2006). The dopamine transporter proteome. Journal of Neurochemistry, 97(Suppl 1), 3–10.
Torres, G. E., Yao, W. D., Mohn, A. R., Quan, H., Kim, K. M., Levey, A. I., et al. (2001). Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron, 30, 121–134.
Unger, E. L., Eve, D. J., Perez, X. A., Reichenbach, D. K., Xu, Y., Lee, M. K., et al. (2006). Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiology of Disease, 21, 431–443.
Wersinger, C., Prou, D., Vernier, P., & Sidhu, A. (2003). Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB Journal, 17, 2151–2153.
Xu, J., Kao, S. Y., Lee, F. J., Song, W., Jin, L. W., & Yankner, B. A. (2002). Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Natural Medicines, 8, 600–606.
Yamada, M., Mizuno, Y., & Mochizuki, H. (2005). Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson’s disease. Human Gene Therapy, 16, 262–270.
Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of Neurology, 55, 164–173.
Zhang, Y., Gao, J., Chung, K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000). Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proceedings of the National Academy of Sciences of the United States of America, 97, 13354–13359.
Acknowledgements
We thank S. W. Zou for technical assistance. A. M. is a recipient of Parkinson Society Canada fellowship. F. J. S. L. is a recipient of a Parkinson Society Canada fellowship and NARSAD Young Investigator award. F. L. is a recipient of McDonald Scholarship of the Heart and Stroke Foundation of Canada. The work is supported by the Canadian Institutes of Health Research (F. L.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moszczynska, A., Saleh, J., Zhang, H. et al. Parkin Disrupts the α-Synuclein/Dopamine Transporter Interaction: Consequences Toward Dopamine-induced Toxicity. J Mol Neurosci 32, 217–227 (2007). https://doi.org/10.1007/s12031-007-0037-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-007-0037-0